DE19927689A1 - Orale Darreichungsformen zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac - Google Patents
Orale Darreichungsformen zur Verabreichung einer fixen Kombination von Tramadol und DiclofenacInfo
- Publication number
- DE19927689A1 DE19927689A1 DE19927689A DE19927689A DE19927689A1 DE 19927689 A1 DE19927689 A1 DE 19927689A1 DE 19927689 A DE19927689 A DE 19927689A DE 19927689 A DE19927689 A DE 19927689A DE 19927689 A1 DE19927689 A1 DE 19927689A1
- Authority
- DE
- Germany
- Prior art keywords
- tramadol
- application unit
- oral application
- diclofenac
- unit according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 title claims abstract description 72
- 229960004380 tramadol Drugs 0.000 title claims abstract description 72
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 title claims abstract description 68
- 229960001259 diclofenac Drugs 0.000 title claims abstract description 38
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 239000004480 active ingredient Substances 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title abstract description 10
- 238000009472 formulation Methods 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 239000008188 pellet Substances 0.000 claims description 40
- 238000000576 coating method Methods 0.000 claims description 26
- 239000011248 coating agent Substances 0.000 claims description 15
- 239000013543 active substance Substances 0.000 claims description 12
- 230000000979 retarding effect Effects 0.000 claims description 12
- 239000011159 matrix material Substances 0.000 claims description 11
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 8
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 238000001125 extrusion Methods 0.000 claims description 6
- 229960003107 tramadol hydrochloride Drugs 0.000 claims description 6
- 238000005563 spheronization Methods 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 4
- 229960001193 diclofenac sodium Drugs 0.000 claims description 4
- 239000003456 ion exchange resin Substances 0.000 claims description 4
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 4
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 3
- 239000004925 Acrylic resin Substances 0.000 claims description 3
- 229920001268 Cholestyramine Polymers 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- KNDHRUPPBXRELB-UHFFFAOYSA-M [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Chemical compound [Cl-].C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 KNDHRUPPBXRELB-UHFFFAOYSA-M 0.000 claims description 3
- 229960001678 colestyramine Drugs 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 3
- 239000002702 enteric coating Substances 0.000 claims description 3
- 238000009505 enteric coating Methods 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 229920003176 water-insoluble polymer Polymers 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- 229960004515 diclofenac potassium Drugs 0.000 claims description 2
- KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 claims description 2
- 238000005342 ion exchange Methods 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 229960001860 salicylate Drugs 0.000 claims description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 229920013820 alkyl cellulose Polymers 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 239000002360 explosive Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 19
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 8
- 239000000463 material Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 3
- 229940124641 pain reliever Drugs 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 229920000178 Acrylic resin Polymers 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- PPKXEPBICJTCRU-UHFFFAOYSA-N [2-hydroxy-2-(3-methoxyphenyl)cyclohexyl]methyl-dimethylazanium;chloride Chemical compound Cl.COC1=CC=CC(C2(O)C(CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- -1 croscarmelose Polymers 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000013563 matrix tablet Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000010309 melting process Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000011970 polystyrene sulfonate Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Priority Applications (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19927689A DE19927689A1 (de) | 1999-06-17 | 1999-06-17 | Orale Darreichungsformen zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac |
| HU0201687A HUP0201687A3 (en) | 1999-06-17 | 2000-06-13 | Oral administration form for administering a fixed tramadol and diclofenac combination |
| EP00942052A EP1185253B1 (de) | 1999-06-17 | 2000-06-13 | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac |
| HK02106641.8A HK1045113A1 (zh) | 1999-06-17 | 2000-06-13 | 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式 |
| AU56805/00A AU778151B2 (en) | 1999-06-17 | 2000-06-13 | Oral administration form for administering a fixed tramadol and diclofenac combination |
| SI200030386T SI1185253T1 (en) | 1999-06-17 | 2000-06-13 | Oral administration form for administering a fixed tramadol and diclofenac combination |
| CA002377174A CA2377174C (en) | 1999-06-17 | 2000-06-13 | Oral administration forms for administering a fixed tramadol and diclofenac combination |
| AT00942052T ATE260650T1 (de) | 1999-06-17 | 2000-06-13 | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac |
| MXPA01013046A MXPA01013046A (es) | 1999-06-17 | 2000-06-13 | Formas de administracion oral para administrar una combinacion fija de tramadol y diclofenac. |
| DK00942052T DK1185253T3 (da) | 1999-06-17 | 2000-06-13 | Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac |
| DE50005529T DE50005529D1 (de) | 1999-06-17 | 2000-06-13 | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac |
| PT00942052T PT1185253E (pt) | 1999-06-17 | 2000-06-13 | Forma de administracao oral para administracao de uma combinacao fixa de tramadol e diclofenac |
| JP2001504359A JP4889897B2 (ja) | 1999-06-17 | 2000-06-13 | トラマドールとジクロフェナクの固定組合せ物を投与するための経口投与形 |
| PCT/EP2000/005386 WO2000078294A2 (de) | 1999-06-17 | 2000-06-13 | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac |
| ES00942052T ES2215680T3 (es) | 1999-06-17 | 2000-06-13 | Unidad unica de administracin que contiene una combinacion de tramadol y diclofenaco. |
| NZ516593A NZ516593A (en) | 1999-06-17 | 2000-06-13 | Oral administration form for administering a fixed Tramadol and Diclofenac combination for treating pain |
| US10/016,130 US20020156133A1 (en) | 1999-06-17 | 2001-12-17 | Oral administration forms for administering a fixed tramadol and diclofenac combination |
| US10/665,552 US8173164B2 (en) | 1999-06-17 | 2003-09-22 | Oral administration forms for administering a fixed tramadol and diclofenac combination |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19927689A DE19927689A1 (de) | 1999-06-17 | 1999-06-17 | Orale Darreichungsformen zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE19927689A1 true DE19927689A1 (de) | 2000-12-21 |
Family
ID=7911586
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19927689A Ceased DE19927689A1 (de) | 1999-06-17 | 1999-06-17 | Orale Darreichungsformen zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac |
| DE50005529T Expired - Lifetime DE50005529D1 (de) | 1999-06-17 | 2000-06-13 | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE50005529T Expired - Lifetime DE50005529D1 (de) | 1999-06-17 | 2000-06-13 | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20020156133A1 (enExample) |
| EP (1) | EP1185253B1 (enExample) |
| JP (1) | JP4889897B2 (enExample) |
| AT (1) | ATE260650T1 (enExample) |
| AU (1) | AU778151B2 (enExample) |
| CA (1) | CA2377174C (enExample) |
| DE (2) | DE19927689A1 (enExample) |
| DK (1) | DK1185253T3 (enExample) |
| ES (1) | ES2215680T3 (enExample) |
| HK (1) | HK1045113A1 (enExample) |
| HU (1) | HUP0201687A3 (enExample) |
| MX (1) | MXPA01013046A (enExample) |
| NZ (1) | NZ516593A (enExample) |
| PT (1) | PT1185253E (enExample) |
| WO (1) | WO2000078294A2 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1364649A1 (en) * | 2002-05-23 | 2003-11-26 | Cilag AG | Adduct of topiramate and tramadol hydrochioride and uses thereof |
| WO2007090393A3 (de) * | 2006-02-10 | 2008-02-21 | Biogenerics Pharma Gmbh | Pharmazeutische zubereitung auf basis vom mikrotabletten |
| US7611730B2 (en) | 2001-02-21 | 2009-11-03 | Grunenthal Gmbh | Tramadol-based medicament |
| CN110755396A (zh) * | 2019-12-06 | 2020-02-07 | 北京悦康科创医药科技股份有限公司 | 一种布洛芬缓释小丸及其制备方法 |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030134810A1 (en) * | 2001-10-09 | 2003-07-17 | Chris Springate | Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents |
| CA2523083C (en) | 2003-04-25 | 2014-07-08 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| US20050265955A1 (en) * | 2004-05-28 | 2005-12-01 | Mallinckrodt Inc. | Sustained release preparations |
| JP2008508291A (ja) | 2004-07-27 | 2008-03-21 | ギリアード サイエンシーズ， インコーポレイテッド | 抗ｈｉｖ剤としてのヌクレオシドホスホネート結合体 |
| US20070009591A1 (en) * | 2005-07-07 | 2007-01-11 | Trivedi Jay S | ACE inhibitor formulation |
| AU2006269225B2 (en) | 2005-07-07 | 2011-10-06 | Farnam Companies, Inc. | Sustained release pharmaceutical compositions for highly water soluble drugs |
| EP1785412A1 (en) * | 2005-11-14 | 2007-05-16 | IPCA Laboratories Limited | Tramadol recovery process |
| CA2645855C (en) | 2006-03-16 | 2015-02-03 | Tris Pharma, Inc. | Modified release formulations containing drug-ion exchange resin complexes |
| JP2008208078A (ja) * | 2007-02-27 | 2008-09-11 | Takada Seiyaku Kk | 分割錠剤 |
| EP2307435B1 (en) | 2008-07-08 | 2012-06-13 | Gilead Sciences, Inc. | Salts of hiv inhibitor compounds |
| DE102008056312A1 (de) | 2008-11-07 | 2010-05-12 | Biogenerics Pharma Gmbh | Verwendung von Mikrotabletten als Lebens-und Futtermittelzusatz |
| JP2013535438A (ja) * | 2010-07-12 | 2013-09-12 | ユン シン ファーマシューティカル インダストリアル カンパニー，リミティド | トラマドールのジクロフェナク塩 |
| US8623409B1 (en) | 2010-10-20 | 2014-01-07 | Tris Pharma Inc. | Clonidine formulation |
| US8287903B2 (en) | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
| DK2884961T3 (en) | 2012-08-15 | 2019-04-23 | Tris Pharma Inc | METHYLPHENIDATE TABLE WITH EXTENDED RELEASE |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| EP3661937B1 (en) | 2017-08-01 | 2021-07-28 | Gilead Sciences, Inc. | Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
| US11918689B1 (en) | 2020-07-28 | 2024-03-05 | Tris Pharma Inc | Liquid clonidine extended release composition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0546676A1 (en) * | 1991-10-30 | 1993-06-16 | Mcneilab, Inc. | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug |
| DE19732928A1 (de) * | 1997-07-31 | 1999-02-04 | Gruenenthal Gmbh | Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8521350D0 (en) * | 1985-08-28 | 1985-10-02 | Euro Celtique Sa | Analgesic composition |
| DE3627423A1 (de) * | 1986-08-13 | 1988-02-18 | Thomae Gmbh Dr K | Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung |
| US5919826A (en) * | 1996-10-24 | 1999-07-06 | Algos Pharmaceutical Corporation | Method of alleviating pain |
-
1999
- 1999-06-17 DE DE19927689A patent/DE19927689A1/de not_active Ceased
-
2000
- 2000-06-13 HK HK02106641.8A patent/HK1045113A1/zh unknown
- 2000-06-13 AT AT00942052T patent/ATE260650T1/de active
- 2000-06-13 WO PCT/EP2000/005386 patent/WO2000078294A2/de not_active Ceased
- 2000-06-13 DK DK00942052T patent/DK1185253T3/da active
- 2000-06-13 CA CA002377174A patent/CA2377174C/en not_active Expired - Fee Related
- 2000-06-13 HU HU0201687A patent/HUP0201687A3/hu unknown
- 2000-06-13 MX MXPA01013046A patent/MXPA01013046A/es active IP Right Grant
- 2000-06-13 JP JP2001504359A patent/JP4889897B2/ja not_active Expired - Fee Related
- 2000-06-13 EP EP00942052A patent/EP1185253B1/de not_active Expired - Lifetime
- 2000-06-13 DE DE50005529T patent/DE50005529D1/de not_active Expired - Lifetime
- 2000-06-13 NZ NZ516593A patent/NZ516593A/en not_active IP Right Cessation
- 2000-06-13 ES ES00942052T patent/ES2215680T3/es not_active Expired - Lifetime
- 2000-06-13 PT PT00942052T patent/PT1185253E/pt unknown
- 2000-06-13 AU AU56805/00A patent/AU778151B2/en not_active Ceased
-
2001
- 2001-12-17 US US10/016,130 patent/US20020156133A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0546676A1 (en) * | 1991-10-30 | 1993-06-16 | Mcneilab, Inc. | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug |
| DE19732928A1 (de) * | 1997-07-31 | 1999-02-04 | Gruenenthal Gmbh | Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7611730B2 (en) | 2001-02-21 | 2009-11-03 | Grunenthal Gmbh | Tramadol-based medicament |
| EP1364649A1 (en) * | 2002-05-23 | 2003-11-26 | Cilag AG | Adduct of topiramate and tramadol hydrochioride and uses thereof |
| WO2003099273A1 (en) * | 2002-05-23 | 2003-12-04 | Cilag Ag | Adduct of topiramate and tramadol hydrochloride and uses thereof |
| US7378519B2 (en) | 2002-05-23 | 2008-05-27 | Cilag Gmbh International | Adduct of topiramate and tramadol hydrochloride and uses thereof |
| WO2007090393A3 (de) * | 2006-02-10 | 2008-02-21 | Biogenerics Pharma Gmbh | Pharmazeutische zubereitung auf basis vom mikrotabletten |
| US8883205B2 (en) | 2006-02-10 | 2014-11-11 | Biogenerics Pharma Gmbh | Microtablet-based pharmaceutical preparation |
| CN110755396A (zh) * | 2019-12-06 | 2020-02-07 | 北京悦康科创医药科技股份有限公司 | 一种布洛芬缓释小丸及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| PT1185253E (pt) | 2004-07-30 |
| DE50005529D1 (de) | 2004-04-08 |
| WO2000078294A3 (de) | 2001-03-29 |
| EP1185253A2 (de) | 2002-03-13 |
| AU778151B2 (en) | 2004-11-18 |
| MXPA01013046A (es) | 2002-06-04 |
| NZ516593A (en) | 2003-08-29 |
| AU5680500A (en) | 2001-01-09 |
| CA2377174A1 (en) | 2000-12-28 |
| CA2377174C (en) | 2009-07-28 |
| WO2000078294A2 (de) | 2000-12-28 |
| US20020156133A1 (en) | 2002-10-24 |
| EP1185253B1 (de) | 2004-03-03 |
| HUP0201687A3 (en) | 2005-07-28 |
| ES2215680T3 (es) | 2004-10-16 |
| DK1185253T3 (da) | 2004-04-05 |
| HK1045113A1 (zh) | 2002-11-15 |
| JP2003502360A (ja) | 2003-01-21 |
| JP4889897B2 (ja) | 2012-03-07 |
| ATE260650T1 (de) | 2004-03-15 |
| HUP0201687A2 (en) | 2002-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1185253B1 (de) | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac | |
| EP1183015B1 (de) | Mehrschichttablette zur verabreichung einer fixen kombination von tramadol und diclofenac | |
| DE19940944B4 (de) | Retardierte, orale, pharmazeutische Darreichungsformen | |
| EP1020185B1 (de) | Opioide Analgetika mit kontrollierter Wirkstofffreisetzung | |
| DE69429826T2 (de) | Opioid-formulierungen zur schmerzbehandlung | |
| EP1207866B1 (de) | Retardierte darreichungsform enthaltend tramadolsaccharinat | |
| EP0519870B1 (de) | Neue orale Diclofenaczubereitung | |
| EP0069259B1 (de) | Bromhexin-Retardform und Verfahren zu ihrer Herstellung | |
| EP0917463B1 (de) | Tramadol multiple unit formulierungen | |
| EP1372624B1 (de) | Arzneimittel auf basis von tramadol | |
| EP0032562A1 (de) | Neue Dipyridamol-Retardformen und Verfahren zu ihrer Herstellung | |
| EP0068191A2 (de) | Orale Dipyridamolformen | |
| DD292374A5 (de) | Verfahren zum herstellen von ueberzugsmaterialien zur steuerung der arzneimittelfreisetzung bei langzeitwirkenden zubereitungen | |
| DE3688031T2 (de) | Galenische formen des verapamils, deren herstellung sowie diese enthaltende arzneimittel. | |
| EP1020183A2 (de) | Analgetikum mit kontrollierter Wirkstofffreisetzung | |
| EP1480623A1 (de) | Arzneimittel mit cholesterolspiegel-senkenden wirkstoffen mit zeitverzögerter wirkstofffreisetzung | |
| US8173164B2 (en) | Oral administration forms for administering a fixed tramadol and diclofenac combination | |
| DE10023699A1 (de) | Retardierte Darreichungsform enthaltend Tramadolsaccharinat | |
| WO2000066088A1 (de) | Metamizol enthaltende, kontrolliert freisetzende pharmazeutische zusammensetzung | |
| MXPA00000603A (en) | Analgesic compositionwith controlled release |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8131 | Rejection |